- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection.
- Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
- Factors predictive of response to hormone therapy in breast cancer.
- Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
- Progression and treatment of HER2-positive breast cancer.
- The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.
- Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial.
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer.
- Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone.
- Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
- Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
- Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial
- EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
- p53 as a specific prognostic factor in triple-negative breast cancer
- Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
- Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment
- Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
